Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis.
Daniel V Araujo, J Connor Wells, Aaron R Hansen, Nazli Dizman, Sumanta K Pal, Benoit Beuselinck, Frede Donskov, Chun L Gan, Flora Yan, Ben Tran, Christian K Kollmannsberger, Guillermo de Velasco, Takeshi Yuasa, M Neil Reaume, D Scott Ernst, Thomas Powles, Georg A Bjarnason, Toni K Choueiri, Daniel YC Heng, Shaan Dudani
Journal of Geriatric Oncology | Published : 2021
OBJECTIVE: Older adults with metastatic renal cell carcinoma(mRCC) are underrepresented in immune-checkpoint inhibitor(ICI) registration trials. Here we compare the efficacy of ICI treatments in older vs. younger adults with mRCC. METHODS: Using the International mRCC Database Consortium(IMDC), patients treated with a PD(L)-1 based ICI were identified. Older adult was defined as ≥70-years at the time of treatment. Descriptive statistics were summarized in means, medians, and proportions. Effectiveness endpoints included overall survival (OS), time-to-treatment failure(TTF), time-to-next treatment(TNT), and overall response rate(ORR). Hazards ratios were adjusted(aHR) for IMDC risk factors, h..View full abstract